Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Steven H Lin, ProfMD"'
Autor:
Maliazurina B Saad, PhD, Lingzhi Hong, MD, Muhammad Aminu, MD, Natalie I Vokes, MD, Pingjun Chen, PhD, Morteza Salehjahromi, PhD, Kang Qin, MD, Sheeba J Sujit, PhD, Xuetao Lu, PhD, Elliana Young, MS, Qasem Al-Tashi, PhD, Rizwan Qureshi, PhD, Carol C Wu, ProfMD, Brett W Carter, ProfMD, Steven H Lin, ProfMD, Percy P Lee, ProfMD, Saumil Gandhi, MD, Joe Y Chang, ProfMD, Ruijiang Li, PhD, Michael F Gensheimer, MD, Heather A Wakelee, ProfMD, Joel W Neal, MD, Hyun-Sung Lee, MD, Chao Cheng, PhD, Vamsidhar Velcheti, ProfMD, Yanyan Lou, MD, Milena Petranovic, MD, Waree Rinsurongkawong, PhD, Xiuning Le, MD, Vadeerat Rinsurongkawong, PhD, Amy Spelman, PhD, Yasir Y Elamin, MD, Marcelo V Negrao, MD, Ferdinandos Skoulidis, MD, Carl M Gay, MD, Tina Cascone, MD, Mara B Antonoff, MD, Boris Sepesi, MD, Jeff Lewis, BS, Ignacio I Wistuba, ProfMD, John D Hazle, ProfPhD, Caroline Chung, MD, David Jaffray, ProfPhD, Don L Gibbons, ProfMD, Ara Vaporciyan, ProfMD, J Jack Lee, ProfPhD, John V Heymach, ProfMD, Jianjun Zhang, MD, Jia Wu, PhD
Publikováno v:
The Lancet: Digital Health, Vol 5, Iss 7, Pp e404-e420 (2023)
Summary: Background: Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availabil
Externí odkaz:
https://doaj.org/article/0a63dfd25a6f4694ab5c9c636dd7ce6b
